Revvity, Inc. · NYSE:RVTY
Revvity — Q4 2021 Earnings Presentation
8 slides from Revvity's earnings presentation, Feb 1, 2022
Slide 1: 4Q21 Earnings Presentation
4Q21 Earnings Presentation February 1, 2022
Slide 2: Safe Harbor
SAFE HARBOR This presentation contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial
Slide 3: 4Q '21 Financial Results
4Q ‘21 FINANCIAL RESULTS Org. Rev Adj Op Adj EPS Revenue Mix (%) & Organic Growth Highlights Decline -9% Margin 850bps Growth -35% DAS Adjusted Revenue: $1.36 billion; +1% y/y 48% +HSD • Organic: -9%; M&A: +11%; FX: -1% DX 52% • COVID: $336 million vs. $549 million in 4Q20 -DD • Non-COVID: +11% orga
Slide 4: 2021 Financial Results
2021 FINANCIAL RESULTS Org. Rev Adj Op Adj EPS Revenue Mix (%) & Organic Growth Highlights Growth 24% Margin 310bps Growth +37% DAS Adjusted Revenue: $5.07 billion; +34% y/y 42% +DD • Organic: +24%; M&A: +8%; FX: +1% DX 58% • COVID: $1.55 billion vs. $1.05 billion in 2020 +DD • Non-COVID: +16% organ
Slide 5: Discovery & Analytical Solutions
DISCOVERY & ANALYTICAL SOLUTIONS ✓ +HSD organic with Pharma up +DD 4Q21 Performance Food* Life ✓ Discovery +DD driven by strength in Sciences reagents & imaging/detection • +30% reported growth ✓ Informatics strong +DD • Organic: +9%; M&A: +22%; FX: -2% • +DD organic growth in Americas & ✓ +MSD orga
Slide 6: Diagnostics
DIAGNOSTICS ✓ +HSD organic growth driven by clinical 4Q21 Performance diagnostics franchise Applied Reproductive Genomics Health ✓ Mixed birth rate trends & lockdown ImmunoDx • -17% reported decline impacts offset by improved utilization & • Organic: -20%; M&A: +4%; FX: -1% menu expansion • Non-COVI
Slide 7: Updated Financial Guidance
UPDATED FINANCIAL GUIDANCE 1Q22 Guidance 2022 Guidance • Adjusted Revenue: $1.17-$1.19 billion; -9% to -11% reported • Adjusted Revenue: $4.42-$4.50 billion; -11% to -13% reported • Organic: -18% to -19%; M&A +11%; FX -2% • Organic: -17% to -18%; M&A +7%; FX -1% Assumptions COVID vs. Non-COVID Outlo
Slide 8: Innovating for a healthier world
INNOVATING for a healthier world Steve Willoughby | Vice President, Investor Relations | steve.willoughby@perkinelmer.com | @PerkinElmerIR 8